SCHEMBL14675490

SCHEMBL14675490

CCCCSc1nc2ccc(OCC)cc2s1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.65
LMNA P02545 5/20 0.65
L3MBTL1 Q9Y468 3/20 0.65
MAPK1 P28482 1/20 0.65
HTT P42858 2/20 0.63
TDP1 Q9NUW8 2/20 0.63
ALOX5 P09917 2/20 0.62
SMN1; SMN2 Q16637 4/20 0.60
PPARA Q07869 3/20 0.58
ALDH1A1 P00352 4/20 0.57
KMT2A Q03164 4/20 0.57
HPGD P15428 3/20 0.57
MEN1 O00255 3/20 0.57
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
CYP3A4 P08684 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C19 P33261 1/20 0.57
HSD17B10 Q99714 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8357492 0.95 MAPT (0.62) MAPTLMNAL3MBTL1MAPK1HTT
SCHEMBL14675442 0.92 MAPT (0.67) MAPTLMNAL3MBTL1MAPK1HTT
SCHEMBL10736645 0.90 MAPT (0.62) MAPTLMNAL3MBTL1MAPK1HTT
SCHEMBL9389944 0.87 MAPT (0.67) MAPTLMNAL3MBTL1MAPK1HTT
SCHEMBL1129400 0.87 MAPT (0.58) MAPTLMNAL3MBTL1MAPK1HTT
SCHEMBL9439898 0.86 MAPT (0.63) MAPTLMNAL3MBTL1MAPK1HTT
SCHEMBL8361491 0.84 MAPT (0.66) MAPTLMNAL3MBTL1MAPK1HTT
SCHEMBL6689290 0.83 PDK1 (0.69) MAPTLMNAL3MBTL1MAPK1HTT
SCHEMBL6902202 0.83 MAPT (0.66) MAPTLMNAL3MBTL1MAPK1HTT
SCHEMBL14675979 0.83 MAPT (0.67) MAPTLMNAL3MBTL1MAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409904-B2 Compounds and compositions for use in augmentation of glucose YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2016-08-09 US disclosed
US-20150025094-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN AUGMENTATION OF GLUCOSE YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2015-01-22 US disclosed
EP-2739612-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN AUGMENTATION OF GLUCOSE UPTAKE AND INSULIN SECRETION Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. (IL) 2014-06-11 EP disclosed
WO-2013018095-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN AUGMENTATION OF GLUCOSE UPTAKE AND INSULIN SECRETION YISSUM RESEARCH AND DEVELOPMENT OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2013-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025094-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN AUGMENTATION OF GLUCOSE SLC5A2, SLC2A2, SLC2A1 MAPT 4597/4885LMNA 1819/4885L3MBTL1 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.